Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
2.140
+0.010 (0.47%)
At close: Nov 6, 2026, 4:00 PM EST
2.300
+0.160 (7.48%)
After-hours: Nov 6, 2026, 5:36 PM EST
Edesa Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
28.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Immutep | 13.79M |
| Metagenomi Therapeutics | 13.56M |
| EyePoint | 2.79M |
| BeyondSpring | 1.88M |
EDSA News
- 2 days ago - Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 22 days ago - Edesa Biotech announces FDA clearance for vitiligo study - TheFly
- 22 days ago - Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study - GlobeNewsWire
- 2 months ago - Edesa Biotech 3.87M share Spot Secondary priced at $5.50 - TheFly
- 2 months ago - Edesa Biotech Announces Pricing of $25.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Edesa Biotech announces offering of common stock and warrants, no amount given - TheFly
- 2 months ago - Edesa Biotech Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results - GlobeNewsWire